News

Article

Pharmaceutical Technology

Pharmaceutical Technology-10-02-2004
Volume28
Issue 10

Preparation and In Vitro Characterization of Self-Nanoemulsified Drug Delivery Systems of Coenzyme Q10 Using Chiral Essential Oil Components

By enhancing stability and in vitro drug-release characteristics, limonene enantiomers are a natural-source alternative for developing and characterizing self-nanoemulsified drug delivery systems.

External Link - article-128365.pdf

Articles in this issue
A Novel Freeze Pelletization Technique for Preparing Matix Pellets
Aseptic Processing: A Review of Current Industry Practice
Can Inserts Be Improved?
Analysis of a Kneading Process to Evaluate Drug Substance-Cyclodextrin Complexation
Drug Development Linked More Closely to Diagnostics
Preparation and In Vitro Characterization of Self-Nanoemulsified Drug Delivery Systems of Coenzyme Q10 Using Chiral Essential Oil Components
In The Spotlight-October 2004
October 2004
Visible-Residue Limit for Cleaning Validation and its Potential Application in Pharmaceutical Research Facility
The High Price of Success
Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up
USP General Notices and General Test Chapters: Interpretations and Misinterpretations
Breaking the Barrier: Advances in Transdermal Technology

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content
Mercury. Element 80 of the periodic table of chemical elements. | Image Credit: © N. Elkha - stock.adobe.com
July 24th 2025

Opposing Reactions as RFK Jr. Removes Thimerosal from Flu Vaccines

Patrick Lavery
Following an overhaul at ACIP, the HHS secretary took the advice of the committee’s new members, saying he was acting on guidance that dated back to 1999.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
June 25th 2024

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
3d render. Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. COVID-19 mRNA vaccine production platform. | Image Credit: © wacomka - stock.adobe.com
July 22nd 2025

Pack Expo Las Vegas Marks 30th Anniversary with New Experiences for 2025

Patrick Lavery
The trade show is expected to draw 35,000 attendees to a show floor netting more than 1 million square feet.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Rueil-Malmaison, France - 13 août 2023: Siège social France de Bristol-Myers Squibb, entreprise pharmaceutique américaine née de la fusion entre Bristol-Myers Company et Squibb Corporation | Image Credit: © HJBC - stock.adobe.com
July 22nd 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Patrick Lavery
Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com
July 21st 2025

FDA Appoints New CDER Director, George Tidmarsh

Susan Haigney
George Francis Tidmarsh, MD, PhD, founding co-director of Stanford’s Master of Translational Research and Applied Medicine program, has been appointed as the new director of the Center for Drug Evaluation and Research.